ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

BACKGROUND: Standard of care for newly diagnosed glioblastoma (GBM) has been chemoradiotherapy with concomitant and adjuvant temozolomide (TMZ) (Stupp regimen). Optimal number of adjuvant TMZ cycles, however, has not been well established yet, although the pivotal trial used 6 cycles. In routine pra...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Neuro Oncol
मुख्य लेखकों: Nagane, Motoo, Kobayashi, Keiichi, Saito, Kuniaki, Shimizu, Saki, Suematsu, Shinya, Kume, Satoshi, Okamura, Yuma, Shiokawa, Yoshiaki
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2018
विषय:
Abstracts
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216401/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.080
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन